<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525496</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01Obs-CHRMT</org_study_id>
    <nct_id>NCT03525496</nct_id>
  </id_info>
  <brief_title>Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents</brief_title>
  <acronym>DHIODE</acronym>
  <official_title>Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional Metz-Thionville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iodinated contrast agents (ICA) are widely used in medical imaging. They provide however a&#xD;
      risk of immediate hypersensitivity reactions (IHS). The risk of anaphylactic shock is&#xD;
      estimated at 1/100 000 injections. Nevertheless, for safety reasons and to limit undesirable&#xD;
      effects, the reintroduction tests are not conducted along similar lines to throughout scan or&#xD;
      arteriography. Moreover, reintroduction protocols are actually not standardized, in terms of&#xD;
      injected volume and doses progression. It should be evaluated the relevance of the&#xD;
      reintroduction tests with injection of a low volume and ensure the absence of reaction during&#xD;
      the ICA injections Under real conditions.&#xD;
&#xD;
      The investigators are assuming that the realization of a provocation test by intravenous&#xD;
      reintroduction with a reduced dose of ICA improves the predictive value of IHS in comparison&#xD;
      with only cutaneous tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study will be to estimate the negative predictive value of the&#xD;
      combination of cutaneous tests and provocation test by intravenous reintroduction in the IHS&#xD;
      to iodinated contrast agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2018</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of immediate hypersensitivity reactions</measure>
    <time_frame>Day 1</time_frame>
    <description>Occurrence of immediate hypersensitivity reactions after an injection of ICA</description>
  </primary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>Allergic Reaction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Major patient who had an iodinated contrast agents reintroduction test&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient&#xD;
&#xD;
          -  Having suffered single-blind reintroduction&#xD;
&#xD;
          -  Having benefited from cutaneous tests and ICA reintroduction test in the framework of&#xD;
             IHS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with delayed hypersensitivity&#xD;
&#xD;
          -  Opposed to use data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHR Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <state>Moselle</state>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iodinated contrast agents</keyword>
  <keyword>Immediate hypersensitivity reactions</keyword>
  <keyword>Reintroduction tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

